Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07220954 | A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234 | PHASE1 | RECRUITING | 21 | — | — | Nov 11, 2025 | Apr 1, 2027 | May 18, 2026 | 1 | United Kingdom |
Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations
Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations
Assess relative bioavailability (rBA) by comparing the pharmacokinetics (PK) of different AZD6234 SC formulations
| Arm | Type | Description |
|---|---|---|
| Sequence ABCD | EXPERIMENTAL | Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment A in Period 1, Treatment B in Period 2, Treatment C in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) |
| Sequence BCAD | EXPERIMENTAL | Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment B in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) |
| Sequence CABD | EXPERIMENTAL | Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment C in Period 1, Treatment A in Period 2, Treatment B in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3) |
| Name | Type | Description |
|---|---|---|
| AZD6234 Formulation 1 | DRUG | AZD6234 Formulation 1 will be administered as a single SC injection |
| AZD6234 Formulation 2 (low concentration) | DRUG | AZD6234 Formulation 2 (low concentration) will be administered as a single SC injection |
| AZD6234 Formulation 2 (high concentration) | DRUG | AZD6234 Formulation 2 (high concentration) will be administered as a single SC injection |
| AZD6234 Formulation 3 | DRUG | AZD6234 Formulation 3 will be administered as a single SC injection |
Inclusion Criteria: * Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive * BMI of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg Exclusion Criteria: * History of any clinically important disease or disorder * History or presence of clinically significant cardiovasc...